References
- CDC. Pertussis–United States, 1997–2000. MMWR 2002; 51(04): 73–6.
- Skowronski DM, De Serres G, Macdonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada. J Inf Dis 2002; 185: 1448–53.
- Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 y community study. Br Med J 1988; 296: 612–4.
- Ramsay ME, Farrington CP, Miller E. Age specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect 1993; 111(1): 41–8.
- Blakely TA, Mansoor O, Baker M. The 1996 pertussis epidemic in New Zeland: vaccine effectiveness. N Z Med J 1999; 112(1085): 118–20.
- Torvaldsen S, Simpson JM, McIntyre P. Effectiveness of pertussis vaccination in New South Wales, Australia, 1996–1998. Eur J Epid 2003; 18: 63–9.
- Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003; 21(17–18): 20024–30.
- van Loo IH, van der Heide HG, Nagelkerke NJ, Verhoef J, Mooi FR. Temporal trends in the population structure of Bordetella pertussis during 1949–1996 in a highly vaccinated population. J Inf Dis 1999; 179: 915–23.
- de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of The Netherlands: observations on surveillance data. Emerg Infect Dis 2000; 6: 348–57.
- Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P69/peractin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine driven evolution. Infect Immun 1998; 66: 670–5.
- Chodorowska M, Kuklinska D. Restrictive analysis of DNA of Bordetella pertussis isolated from cases of pertussis in 1968 and in 1995–1998 and also from strains used for production of antipertussis vaccine used in Poland. Med Dos Mikrobiol 200; 52: 111–7.
- Gzyl A, Augustynowicz E, Ślusarczyk J. Sequence analysis of pertussis toxin and pertractin of Bordetella pertussis strains in context of effectiveness of anti-pertussis vaccinations. I Med J Exp Clin Res 2000; 6(Suppl 3): 114.
- Gzyl A, Augustynowicz E, van Loo I, Slusarczyk J. Temporal nucleotide changes in peractin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 2001; 20: 299–303.
- Zielinski A, Czarkowski MP Effectiveness of vaccinations against pertussis at the time of the 1997–1998 epidemic. Polsce Przegl Epidemiol 2001; 55: 207–16.
- Ślusarczyk J, Dulny G, Nowak K, Kryszyna J, Wysokinska T, Fordymacka A, et al. Immunity of children aged 6–8 against pertussis, tetanus and diphtheria. Przegl Epidemiol 2002; 56: 39–48.
- Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Epidemiol Rev 1988; 10: 212–41.
- Cameron AC, Trived PK. Regression Analysis of Count Data. Cambridge, UK: Cambridge University Press; 1998.
- Khattak MN, Mathews RC, Burnie JP. Is Bordetella pertussis clonal? Br Med J 1992; 304: 813–5.
- Guiso N, Borsaux-Eude C, Weber C, Hausman SZ, Sato H, Iwaki M, et al. Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine 2001; 19: 3248–52.